Institutional members access full text with Ovid®

Share this article on:

A Phase I Dose-escalation Study to Evaluate Tolerability in a Western Population to T89, a Modern Cardiovascular Herbal Medicine

Ling, Shanhong MD, PhD*; Luo, Rui-Zhi MS; Nheu, Lina BSc (Hons)*; Guo, Zhi-Xin PhD; Sun, He PhD; Komesaroff, Paul A. MD, PhD*

Journal of Cardiovascular Pharmacology: December 2012 - Volume 60 - Issue 6 - p 513–519
doi: 10.1097/FJC.0b013e31826f6179
Original Article

Abstract: T89 (Dantonic) is a modern herbal medicine currently used in Chinese hospitals for the management of ischemic heart disease. This dose-escalation clinical trial aims to assess tolerability of Western people to T89. Healthy Australian adults of non-Asian background orally took a single dosage of 6, 8, 10, 12, 13, 14, 15, or 16 T89 capsules (6 people for each dose) and were assessed with respect to symptoms and physical signs, electrocardiogram, hematology, plasma biochemistry, and urinalysis. Secondary objectives were to determine the dose-limiting toxicity and maximum-tolerated dose. It found that a single dose of T89 up to 16 capsules was not associated with significant adverse events or abnormalities in clinical laboratory tests and electrocardiogram parameters, except minor symptoms reported included mild and transient dizziness, stomach discomfort, diarrhea, and involuntary muscular contraction. The incident rate of these symptoms was generally low (1/30, 3.3%) but increased (7/18, 38.9%) in higher dose (≥14 capsules) groups. No defined dose-limiting toxicity events occurred; so the study could not define the maximum-tolerated dose. In conclusion, a single dose of T89 up to 13 capsules, 4 times of a regular therapeutic dosage, is generally safe and tolerated by individuals of non-Asian background.

*Department of Medicine, Monash University Central Clinical School, Alfred Center, Melbourne, Victoria, Australia

Tasly R&D Institute, Tasly Pharmaceutical Co, Ltd, Tianjin, China.

Reprints: Shanhong Ling, MD, PhD, Department of Medicine, Monash University Central Clinical School, Alfred Center, 99 Commercial Rd, Prahran, Melbourne, Victoria 3181, Australia (e-mail:

Supported by a research grant (No. 2009DFA30960) from National Department of Sciences and Technology of China.

RZ Luo, ZX Guo, and H Sun are employees of Tasly Pharmaceuticals. The other authors declare no conflicts of interest.

Clinical trial registered No.: ACTRN12609001012268.

Received June 6, 2012

Accepted August 15, 2012

© 2012 Lippincott Williams & Wilkins, Inc.